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Although European Laboratories Welcome Free Use of BRCA2, Access Still in Question
The groups claimed, among other things, that the Myriad patents lacked several criteria for patenting, such as "novelty" and "inventive step," the latter meaning an invention cannot be obvious. In addition, patenting something unique such as a gene means no one can improve on the product.
A similar consortium of European centers and research institutes last year filed an opposition against the BRCA2 patent, again in parallel with the French. "One of the reasons was to clarify the unusual situation involving the two patents on one gene, which is very confusing," said Matthijs. "The other reason is that the same arguments as to BRCA1 apply: there was an international consortium that has worked together on the identification of the gene, and in that context, the cloning itself does not constitute an invention in our view."
For now, it is unclear if CRT's announcement has really changed anything, Matthijs said. "No one knows what the practical result will be," he said. "In principle, one would need a license from both patent owners to use the invention. But it is very strange and very unusual, especially if one patentee is ready to offer a (royalty-free) license and the other is not." "Myriad and CRT must have an agreement on the use of the patents for genetic testing," including royalties, said Dominique Stoppa-Lyonnet, M.D., Ph.D., head of the department of genetics of the medical division of the Curie Institute.
Matthijs said the discussion over the status of BRCA2 patents illustrates the need for improved legislation on gene licensing in Europe. In May, the EPO will meet in Munich to rule on the validity of the opposition to the first of Myriad's European patents. StoppaLyonnet is cautiously optimistic about the European opposition's case. "If the first Myriad patent on BRCA1 is revoked, then now with the free licensing offered by CRT, we may be able to work out solutions for both BRCA1 and BRCA2," she said.
"Under the existing law, even resolute opponents of patenting genes will have to accept paying royalties," Matthijs said. At the same time, "A novel system for rewarding patent owners may have to be put in place." The French are trying. They are seeking a compromise in promoting so-called compulsory licensing in which a judge decides on licensing to various European laboratories and royalties based on the "market."
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